louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04223921: Therapeutic Optimization in Patients in Acute Geriatric Care at University Hospital of Montpellier
Official title: Therapeutic Optimization in Patients in Acute Geriatric Care at University Hospital of Montpellier: Follow-up One Month After Discharge From Hospital
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Geriatrics
Clinical Pharmacy
Keywords: Medication reconciliation
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2020-01-13
Enrollment: 500
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who will be discharged from hospital (acute geriatric care unit) between January and March 2020

Brief summary: This study involves patients who will be discharged from Montpellier University Hospital (acute geriatric care unit) between January and March 2020.

The primary objective is to assess the number of difference(s) in patient's medicines between the discharge from hospital (acute geriatric care unit) and one month after this discharge.

The secondary objectives are:

* to assess the number of changes of medicines between the patient's admission and discharge from hospital (acute geriatric care unit);
* to evaluate the number of inappropriate medicines in patient's treatment at hospital admission (in acute geriatric care unit) and one month after the discharge from hospital;
* to evaluate the number of failures found in the transmission of information between the hospital and the general practitioner/pharmacy one month after the patient's discharge from hospital (acute geriatric care unit).


Eligibility criteria: Inclusion Criteria:

* patients who will be discharged from hospital (acute geriatric care unit) between January and March 2020 and who will return to their home or to institution for elderly persons
* patients for whom there will be at least one change in their medicines between their admission and their discharge from hospital

Exclusion Criteria:

* Patients who don't want to participate in this study

Primary outcomes:
measure: Number of medicines prescribed
timeFrame: One month after discharge from hospital (acute geriatric care unit)
Secondary outcomes:
measure: Number of medicines' changes
timeFrame: At patient's discharge from hospital (acute geriatric care unit)
Other outcomes:
measure: Number of inappropriate medicines in patient's treatments
timeFrame: At hospital admission (in acute geriatric care unit)
measure: Number of inappropriate medicines in patient's treatments
timeFrame: One month after discharge from hospital (acute geriatric care unit)
measure: Number of failures found in the transmission of information between the hospital and the general practitioner/pharmacy
timeFrame: One month after patient's discharge from hospital (acute geriatric care unit)
Locations:
city: Montpellier
country: France
facility: UH Montpellier
Study officials:
affiliation: UH MONTPELLIER
name: DELINGER FAURE, Ph D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05388721: Correlation Between Environmental Pollution and Gestational Diabetes Mellitus
Official title: Correlation Between Environmental Pollution and Gestational Diabetes Mellitus
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Gestational Diabetes Mellitus
Lead sponsor: Women's Hospital School Of Medicine Zhejiang University
Sponsor class: OTHER
First posted: 2022-05-24
Enrollment: 2500
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This project intends to recruit pregnant women who go to the research center for routine prenatal examination and OGTT screening.

Brief summary: Gestational diabetes mellitus (GDM) refers to the abnormal glucose metabolism index of pregnant women during pregnancy. At present, about 15% of pregnant women will develop GDM in the second and third trimester, which seriously affects the health of the pregnant woman and the fetus. However, the etiology of GDM remains unclear. Various pollutants in the environment may have a potential impact on pregnant women and fetuses. For example, previous studies have shown that exposure to atmospheric pollutants nitric oxide and organochlorine pesticides are associated with GDM. At present, we plan to further investigate the correlation between environmental pollutants and GDM.


Eligibility criteria: Inclusion Criteria:

* Plan to complete OGTT and give birth in the research center
* First trimester
* Singleton pregnancy
* Without diabetes before pregnancy

Exclusion Criteria:

* Have diseases that affect metabolic function or even threaten the life of the mother and fetus before pregnancy, such as diabetes, hypertension, heart disease, liver and kidney diseases, thyroid diseases with drug, autoimmune diseases, malignant tumors, AIDS, etc.
* Fetus has a known deformity or genetic defects
* Incomplete clinical data
* Assisted reproductive

Primary outcomes:
measure: Environmental contaminants 1
timeFrame: First trimester (9-14 gestational weeks)
measure: Environmental contaminants 2
timeFrame: Third trimester (after 28 gestational weeks)
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Women's Hospital School Of Medicine Zhejiang University
state: Zhejiang
Study officials:
References:
Clinical trial NCT06586021: Evaluation of the Aortoseal™ for Sealing and Fixation of AAA Endovascular Grafts to Aortic Wall
Official title: SEAL - Safety & Feasibility Evaluation of the Aortoseal™ for Seal and Fixation of Abdominal Aortic Aneurysms (AAA) Endovascular Grafts to the Aortic Wall"
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Abdominal Aortic Aneurysm (AAA)
Lead sponsor: Endoron Medical
Sponsor class: INDUSTRY
First posted: 2024-09-19
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The Aortoseal Endostapling System is indicated in patients undergoing, or having undergone, treatment of an abdominal aortic aneurysm (AAA) with an endovascular graft to provide enhanced fixation and apposition to the aorta.

Detailed description: The device may be implanted at the time of the initial endovascular graft procedure to maintain, or during a secondary procedure to restore, adequate aneurysm.

The study includes 5 years of follow-up, with visits at 30 days, 6 months, 1 year, and yearly thereafter through 5-years.

Follow-up assessments: Physical examination, X-ray, CT (with and without contrast) and assessments of any adverse events.

Eligibility criteria: Subjects diagnosed with a qualifying AAA suitable for elective endovascular repair with Endovascular Graft System or have a previously placed endovascular graft.

Primary outcomes:
measure: Rate of Major Adverse Events
timeFrame: through 5 years
measure: Access Site Complications
timeFrame: through 30 days
measure: All Adverse Events
timeFrame: through 5 years
measure: Endpoints related to Aortoseal Endostapling System
timeFrame: through 5 years
measure: Device Technical Success
timeFrame: during procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Norfolk
country: United States
facility: Sentara Health Research Center
state: Virginia
Study officials:
References:
Clinical trial NCT04711421: Using Pedometers for the Assessment and Enhancement of Mobility in Gynaecological and Oncological Patients Following Surgery.
Official title: Using Pedometers for the Assessment and Enhancement of Mobility in Gynaecological and Oncological Patients Following Surgery.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Surgery
Mobilization
Gynecologic Cancer
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2021-01-15
Enrollment: 150
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a prospective cohort study, planned to study the effects of pedometers (digital step counters) on patient mobility following gynecology and gynecology oncology surgeries. The investigators plan to study the effect of personalized repeated feedback approach based on pedometer results in patients following gynecology and gynecology oncology surgeries.


Eligibility criteria: Inclusion Criteria:

Patients following gynecology and gynecology oncology surgery Consent to participation No medical recommendation for bed rest and limited mobility

Exclusion Criteria:

Refusal to participate Medical recommendation to limit mobility

Primary outcomes:
measure: Number of steps per day during the hospitalization period
timeFrame: Up to 1 week
Secondary outcomes:
measure: Number of participants with complication following surgery
timeFrame: Up to 1 week
measure: Number of analgesic doses
timeFrame: Up to 1 week
measure: Length of hospitalization
timeFrame: Up to 4 week
measure: Number of thromboembolic events
timeFrame: Up to 4 week
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Tel Aviv Medical Center
Study officials:
References:
citation: Ganer Herman H, Kleiner I, Tairy D, Gonen N, Ben Zvi M, Kovo M, Bar J, Weiner E. Effect of Digital Step Counter Feedback on Mobility After Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol. 2020 Jun;135(6):1345-1352. doi: 10.1097/AOG.0000000000003879.
Clinical trial NCT00439621: Safety Study of Anti-IgE Immunotherapy in Allergic Patients
Official title: A Randomized, Double-Blind, Placebo-Controlled Safety and Tolerability Study of Repeated Doses of Anti-IgE Immunotherapy in Allergic Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Allergy
Keywords: immunotherapy
allergy
Lead sponsor: Resistentia Pharmaceuticals AB
Sponsor class: INDUSTRY
First posted: 2007-02-23
Enrollment: 42
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate safety and efficacy of three doses and two dosing regimens of RP01 as an anti-IgE immunotherapy in allergic patients.

Detailed description: Immunotherapy is based on the principle of eliciting an immune reaction in order to block the negative effect of a specific disease-causing protein. The potential to treat diseases by means of immunotherapy instead of using conventional drugs represents an attractive opportunity in a number of chronic disease areas, including asthma and allergy. Resistentia's model to treat allergic diseases, and ultimately asthma, is to use the immune system to produce antibodies against the IgE molecules themselves. The resulting anti-IgE antibodies intercept and form complexes with the IgE molecules before they can bind to the mast cells and basophils and are thus able to block any allergen-triggered inflammatory reaction. The approach works in all types of IgE-mediated allergies independently of allergen, and also in patients sensitive to multiple allergens.

Comparisons: Three doses and two dosing regimes of RP01 will be compared as regards safety and effect.

Eligibility criteria: Inclusion Criteria:

* Allergy to at least one aero allergen
* Increased serum IgE level

Exclusion Criteria:

* Diagnosis of asthma
* Recent use of systemic corticosteroids or immunosuppressive treatment
* Allergy vaccination therapy

Primary outcomes:
measure: Adverse Events
timeFrame: 0-12 months
Secondary outcomes:
measure: Immune kinetic parameters
timeFrame: 0-12 months
Other outcomes:
Locations:
city: Tauranga
country: New Zealand
facility: P3 Research
city: Wellington
country: New Zealand
facility: P3 Research
Study officials:
affiliation: Resistentia Pharmaceuticals AB
name: Vidar Wendel-Hansen, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01889121: Utility of Psychosocial Intervention in Improving Outcome for Methadone-exposed Infants and Their Mothers
Official title: Retrospective Analysis of the Utility Formal Psychosocial Support in Enhancing the Outcome of Pregnancies in Opiate-addicted Pregnant Women in Agonist Maintenance Programs
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neonatal Abstinence Syndrome
Lead sponsor: Children's Hospital Medical Center, Cincinnati
Sponsor class: OTHER
First posted: 2013-06-28
Enrollment: 113
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Opiate abusing pregnant women who received their prenatal care through Good Samaritan Faculty Medical Center and were getting methadone maintenance therapy

Brief summary: Opiate drug abuse/addiction is a significant co-morbidity in pregnancy. Opiate maintenance program enhances the outcome of pregnancies for the mother and the infant. Our objective was to assess if provision of structured psychosocial support in addition to methadone maintenance program adds incremental benefits with regards to the outcome of pregnancy.


Eligibility criteria: Inclusion Criteria:

* Positive Methadone tox screen
* Received care at Good Samaritan Hospital in Cincinnati
* Delivered at Good Samaritan Hospital

Exclusion Criteria:

* Twin gestation
* Sever congenital anomalies
* Conditions requiring transfer to quaternary hospital

Primary outcomes:
measure: Percentage of newborns in each group that required pharmacological treatment for neonatal abstinence syndrome
timeFrame: Birth until discharge
Secondary outcomes:
measure: Gestational age at which the infants were delivered.
timeFrame: Gestational age at delivery.
measure: Percentage of infants that are small for gestational age.
timeFrame: Gestional period.
measure: Anthropometric measurements at birth
timeFrame: Measurements at birth.
Other outcomes:
Locations:
city: Cincinnati
country: United States
facility: Good Samaritan Hospital
state: Ohio
Study officials:
References:
Clinical trial NCT02403921: Association Between Cortisol, Cortisone, Cotinine, Nicotine, Caffeine, Melatonin Levels in Hair, Serum, Urine, Saliva and Chronic Stress
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hydrocortisone
Keywords: biomarker
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2015-03-31
Enrollment: 80
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: adult volunteer

Brief summary: The investigators aim to investigate the association between hair, serum, urine and saliva to measure cortisol, cortisone, cotinine, nicotine, melatonin and caffeine.


Eligibility criteria: Inclusion Criteria:

* adult volunteer

Exclusion Criteria:

* students of the study host
* people who have steroid or melatonin medicine

Primary outcomes:
measure: Chinese Health Questionnaire (CHQ)
timeFrame: 5 minutes
measure: Hospital Anxiety and Depression Scale (HADS)
timeFrame: 5 minutes
measure: Pittsburgh Sleep Quality Index (PSQI)
timeFrame: 5 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Test1
country: Taiwan
facility: National Taiwan University Hospital
state: Test2
Study officials:
affiliation: National Taiwan University
name: Pau-Chung CHEN
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06821321: Power or Plyometric Training in Older Adults
Official title: The Effects of Plyometric or Resistance Training on Muscle and Tendon Stiffness, and Functional Performance in Older Adults
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Activity, Motor
Lead sponsor: University of Miami
Sponsor class: OTHER
First posted: 2025-02-11
Enrollment: 40
Sex: ALL
Minimum age (years): 55
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will compare the effects of high-speed power resistance training or plyometric jump training on muscle stiffness, jump performance and measures of daily activity in older adults living independently in the community.


Eligibility criteria: Inclusion Criteria:

* Independently living
* Between 55-90 years of age

Exclusion Criteria:

* Uncontrolled cardiovascular disease that prevents participation in a training program.
* Documented HIV infection or another immunodeficiency syndrome.
* Current neuromuscular diseases that prevent exercise.
* Current musculoskeletal injury that prevents exercise.
* Incarcerated individuals
* Montreal Cognitive Assessment (MoCA) Score below 18

Primary outcomes:
measure: Change in Quadriceps Muscle Stiffness measured by Kilopascals
timeFrame: Baseline, 10 weeks
measure: Change in Triceps Surae Muscle Stiffness measured by Kilopascals
timeFrame: Baseline, 10 weeks
measure: Change in Quadriceps Tendon Stiffness measured by Kilopascals
timeFrame: Baseline, 12 weeks
measure: Change in Patellar Tendon Stiffness measured by Kilopascals
timeFrame: Baseline, 12 weeks
measure: Change in Achilles Tendon Stiffness measured by Kilopascals
timeFrame: Baseline, 12 weeks
measure: Changes in Stored Elastic Energy measured by joules
timeFrame: Baseline, 12 weeks
measure: Change in Gait Economy
timeFrame: Baseline, 12 weeks
Secondary outcomes:
measure: Change in Muscle Thickness measured in centimeters
timeFrame: Baseline, 12 weeks
measure: Change in Muscle Quality measured using grayscale
timeFrame: Baseline, 12 weeks
measure: Change in neuromuscular performance as measured by 1-repetition maximum (1RM).
timeFrame: Baseline, 12 weeks
measure: Change in the Speed of the Ten-Meter Walk Test.
timeFrame: Baseline, 12 weeks
measure: Change in Time for the Five Times Sit-to-Stand Test.
timeFrame: Baseline, 12 weeks
measure: Change in Distance of the Seated Medicine Ball Throw.
timeFrame: Baseline, 12 weeks
measure: Changes in the Six-Minute Walk Test.
timeFrame: Baseline, 12 weeks
measure: Change in the time required to complete the timed Up-and-Go Test.
timeFrame: Baseline, 12 weeks
measure: Change in neuromuscular performance as measured by Watts
timeFrame: Baseline, 12 weeks
Other outcomes:
Locations:
city: Coral Gables
country: United States
facility: Laboratory of Neruomuscular Research and Active Aging
state: Florida
Study officials:
affiliation: University of Miami
name: Joseph F. Signorile, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01049321: The Effect of DASH Diet on the Cardiometabolic Risks and Hepatic Function Among Type 2 Diabetic Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Type 2 Diabetic Patients
Keywords: Dietary Approach to Stop Hypertension
weight
coagulation
DASH eating pattern.
Lead sponsor: Isfahan University of Medical Sciences
Sponsor class: OTHER
Collaborators: name: Shahid Motahari Hospital of Fooladshahr, Isfahan Steel Company, Isfahan
First posted: 2010-01-14
Enrollment: 36
Sex: ALL
Minimum age (years): 44
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The investigators are not aware of any study regarding the effect of DASH eating pattern on different cardiovascular risks among type 2 diabetic patients. The investigators assumed that DASH eating pattern could reduce the cardio-metabolic risks and improve the hepatic function among type 2 diabetes.


Eligibility criteria: Inclusion Criteria:

* Having type 2 diabetes

Exclusion Criteria:

* Having other chronic disease, hepatic or kidney disorders, cancer, hormone therapy

Primary outcomes:
measure: Cardio-metabolic risks
timeFrame: 6 months
Secondary outcomes:
measure: Hepatic function
timeFrame: 6 months
Other outcomes:
Locations:
city: Isfahan
country: Iran, Islamic Republic of
facility: Shahid motahari hospital, Esfahan Esteel company, Iran
Study officials:
affiliation: Isfahan University of Medical Sciences
name: Leila Azadbakht, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Azadbakht L, Surkan PJ, Esmaillzadeh A, Willett WC. The Dietary Approaches to Stop Hypertension eating plan affects C-reactive protein, coagulation abnormalities, and hepatic function tests among type 2 diabetic patients. J Nutr. 2011 Jun;141(6):1083-8. doi: 10.3945/jn.110.136739. Epub 2011 Apr 27.
Clinical trial NCT04064021: Acupuncture Treatment for Improving Alzheimer's Dementia
Official title: Clinical Trial to Measure Efficacy of Acupuncture Treatment for Alzheimer's Dementia as Measured by MOCA(Montreal Cognitive Assessment)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Cognitive Deficits
Alzheimer Disease
Keywords: Acupunture
Lead sponsor: N & S Neurology Center, A Medical Group, Inc
Sponsor class: INDUSTRY
First posted: 2019-08-21
Enrollment: 0
Sex: ALL
Minimum age (years): 60
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Evaluate cognitive improvement pre amd post acupuncture treatment in patients with probable alzheimer's dementia as measured by MOCA score and also per form A( measure of patient's personal information). Also caregiver input.

Detailed description: Patient's with diagnosis of probable mild to moderate AD will be enrolled in this study. Patient will undergo neurological examination including MOCA. Examiner will also fill out Form A at the time of initial evaluation.

Patient will then undergo series of acupuncture treatments 2 per week for 6 weeks(12 acupuncture treatment). At end of this intervention patients will be reassessed using same testing(MOCA and form A) Data collected will be assessed via statistical analysis to see if there is any statistically significant improvement.

Acupuncture points used in this trial will stay the same for all subjects and throughout the course. The points will be Si Shen Chong, ST36, 37, LV 2,3,6, GB 34, 39, Xia San Huang, LI 11, LI 4.

Eligibility criteria: Inclusion Criteria:

* Mild to moderate AD

Exclusion Criteria:

* Severe AD

Primary outcomes:
measure: Improvement on Montreal Cognitive Assessment test of 5 points or more than baseline( total score is out of 30 points)
timeFrame: 12 weeks
Secondary outcomes:
measure: Improvement of Montreal Cognitive Assessment test by category than raw total score
timeFrame: 12 weeks
Other outcomes:
Locations:
Study officials:
affiliation: N & S Neurology Center, A Medical Group, Inc
name: SANJAY CHAUHAN, M.D.
role: PRINCIPAL_INVESTIGATOR
References: